Abstract
Background
Irinotecan is chemotherapeutic agent often used in abdominal cancers such as colorectal and pancreatic cancers. While often associated with non-central nervous system (CNS) adverse effects, in rare cases it may present with paresthesias and dysarthrias. In one case, a patient received an irinotecan-containing regimen (fluorouracil, irinotecan, oxaliplatin) and experienced several neurotoxic effects, which was successfully managed.
Case Report
A female patient with newly-diagnosed pancreatic cancer was started on fluorouracil, irinotecan, and oxaliplatin (modified FOLFIRINOX). She developed dysarthrias early on in the course. Causality assessment was conducted via the Naranjo criteria, yielding a score of 6, indicating a probable adverse reaction.
Management & Outcome
Initially managed with steroids and lorazepam, she was eventually given a prophylactic strategy of atropine 0.4 mg and a longer infusion time of 3 h instead of 90 min with as needed lorazepam. This strategy alleviated the dysarthrias and the patient was able to complete 12 cycles of therapy, resulting in a partial response at the end of treatment.
Discussion
Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.
Get full access to this article
View all access options for this article.